Drug Profile

Lenvatinib - Eisai Co Ltd/Merck & Co

Alternative Names: E 7080; ER-203492-00; Kisplyx; KYSPLIX; Lenvatinib mesylate; LENVIMA; Lenvima; MK 7902

Latest Information Update: 07 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eisai Co Ltd
Developer Curie Institute; Eisai Co Ltd; EMD Serono; Massachusetts Eye and Ear; Merck & Co; Merck Sharp & Dohme; MSD KK; National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Eye disorder therapies; Phenyl ethers; Quinolines; Small molecules; Urea compounds
Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Thyroid cancer; Liver cancer; Endometrial cancer; Malignant melanoma
New Molecular Entity Yes

Marketed Endometrial cancer; Liver cancer; Renal cell carcinoma; Thyroid cancer
Registered Malignant thymoma
Phase III Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
Phase II Biliary cancer; Glioblastoma; Kaposi's sarcoma; Malignant-mesothelioma; Merkel cell carcinoma; Neuroendocrine tumours; Osteosarcoma; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uveal melanoma
Phase I/II Breast cancer
No development reported CNS cancer; Ovarian cancer
Discontinued Cancer; Glioma; Lymphoma

29 Oct 2025 Updated efficacy and adverse events data from the phase III LEAP-012 trial in Liver cancer released by Eisai
21 Oct 2025 Merck Sharp & Dohme completes a phase-II clinical trial in Renal cell carcinoma (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in US, Australia, Canada, France, Hungary, Ireland, Italy, Spain, South Korea, Poland, Russia, Turkey, Ukraine and United Kingdom (PO) (NCT04704219)
27 Aug 2025 Discontinued - Phase-III for Oesophageal cancer (Metastatic disease, First-line therapy, Combination therapy) in Ukraine, Turkey, Russia, China, Costa Rica, Denmark (PO) (Eisai pipeline, August 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com